2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.117 (Poster) Real-World Effectiveness and Safety Pro le of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer

PP01.117 (Poster) Real-World Effectiveness and Safety Pro le of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer

Back to course

Pdf Summary

A study presented at the IASLC 2023 North America Conference on Lung Cancer evaluated the real-world effectiveness and safety profile of lurbinectedin and other second-line treatments (OST) in patients with small cell lung cancer (SCLC). Lurbinectedin received accelerated approval by the US FDA as a monotherapy for metastatic SCLC in June 2020. The study used real-world data from the Flatiron Health EHR database and analyzed response rates, progression endpoints, and adverse events of special interest (AESIs) in the overall population and in subgroups with different chemotherapy-free intervals (CTFI) after platinum-based chemotherapy.<br /><br />The results showed that in the overall population, there were similar effectiveness outcomes between patients treated with lurbinectedin monotherapy (LM) and those treated with OST. However, LM was associated with lower rates of grade 3 thrombocytopenia and anemia, as well as fewer outpatient visits. In patients with platinum-sensitive disease, there was a suggestion of better effectiveness outcomes with LM, but the results in the subgroup with a CTFI of 180 days were limited by the small sample size.<br /><br />Safety outcomes were comparable between LM and OST in both the primary and contemporaneous cohorts. However, LM was associated with lower rates of grade 3 thrombocytopenia and anemia, as well as fewer outpatient visits, in the contemporaneous cohort. It is worth noting that patients in both treatment arms had poor prognostic factors compared to those seen in clinical trials.<br /><br />Overall, the study suggests that lurbinectedin has real-world effectiveness and a favorable safety profile in patients with SCLC. Further research is needed to confirm these findings and explore the optimal use of lurbinectedin in different patient populations.

Asset Subtitle

Nileesa Gautam

Keywords

IASLC 2023

North America Conference on Lung Cancer

real-world effectiveness

safety profile

lurbinectedin

second-line treatments

small cell lung cancer

metastatic SCLC

accelerated approval

US FDA